Compare Hyatt Hotels Corporation (H) vs Medtronic PLC (MDT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hyatt Hotels Corporation vs Medtronic PLC — how do they compare? Hyatt Hotels Corporation trades at $189 (market cap $17.85B), while Medtronic PLC trades at $83.21 (market cap $106.61B). The key difference: Medtronic PLC is far larger — about 6× Hyatt Hotels Corporation's market cap, and Medtronic PLC pays the higher dividend (3.46%). Which is the better fit depends on your goals.
| H | MDT | |
|---|---|---|
Market Cap | $17.85B | $106.61B |
Sector | Consumer Cyclical | Health |
52-Week High | $202.09 | $105.35 |
52-Week Low | $135.01 | $73.75 |
Enterprise Value | $21.69B | $125.36B |
Dividend Yield | 0.32% | 3.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hyatt Hotels (H) trades at $189.75, down 0.47% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $198. Recent earnings show mixed results, with Q2 2026 expected at $0.89 EPS. The company maintains strategic expansions, including new hotel openings and partnerships, while facing profitability challenges with a negative net income margin of -0.48% in 2025.
The stock presents a moderate buy opportunity with analyst support, but risks include declining cash flows and elevated debt. Upside hinges on execution of growth initiatives and improved earnings, while macroeconomic pressures on travel demand pose headwinds. Investors should weigh the 37.5% buy rating against fundamental weaknesses.
Medtronic (MDT) trades at $83.54, up 0.41% today, with a bullish technical signal from moving averages. The company reported strong revenue growth to $33.54B in 2025 and has beaten EPS estimates for three consecutive quarters. Recent acquisitions, including SPR and Scientia Vascular, expand its pain therapy and neurovascular portfolios. Valuation ratios show a P/E of 22.31 and P/S of 2.95, with a consensus price target of $97.50 implying significant upside.
The outlook is positive, supported by robust fundamentals, analyst optimism, and strategic expansions. Key risks include rising debt levels and competitive pressures in medical technology. With no sell ratings from analysts and a dividend yield near a decade high, MDT presents a compelling long-term opportunity for growth and income investors, though macroeconomic and execution risks warrant monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Hyatt Hotels Corporation
Hyatt is an operator of 1,162 owned (5% of total rooms) and managed and franchise (95%) properties across roughly 20 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, and the wellness brand Miraval. Hyatt acquired Two Roads in November 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 66% Americas, 18% Asia-Pacific, and 16% rest of world.
Read more on H →About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →
